Postgraduate research

Cancer Studies

Cancer prevention

Professor Karen Brown

  • Preclinical and early clinical development of novel cancer chemopreventive agents

  • Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy

Professor Don J. L. Jones

  • Translation of candidate biomarkers to clinical use.

  • Use of high resolution LC-MS in the discovery and verification of biomarkers.

  • Investigation of protein quantification using Ion mobility.

  • Translation of candidate biomarkers to clinical use.

  • Use of high resolution LC-MS in the discovery and verification of biomarkers.

  • Investigation of protein quantification using Ion mobility.

Dr Alessandro Rufini

  • Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

  • Investigating and exploiting metabolic vulnerabilities in carcinogenesis

  • Using circulating cell-free DNA for early detection of cancer

Professor Anne Thomas

  • The design and delivery of early phase clinical studies including chemoprevention strategies

  • Improving information exchange in oncology consultations

Dr Cristina Tufarelli 

  • Determine which repetitive elements are active in precancerous and cancerous cells

  • Understanding what causes activation of repetitive elements

  • Establish activation of which repetitive elements plays functional roles in cancer

  • Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

 

Liquid biopsy for early detection and stratification of cancer

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies

  • Antibody therapy of lymphoid malignancies

  • Development and assessment of novel agents for therapy of B-cell malignancies   

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy

  • Molecular approaches to aid early detection of cancer

  • Molecular mechanisms of resistance to targeted therapy

Dr David Guttery

  • Analysis of circulating cancer biomarkers through liquid biopsy

  • Molecular approaches to aid early detection of cancer

  • Molecular mechanisms of resistance to targeted therapy

  • Utility of artificial intelligence for early detection and improving therapy stratification

Dr Esther Moss

  • Analysis of circulating endometrial cancer biomarkers through liquid biopsy

  • Robotic surgery for management of endometrial cancer

  • Patient-initiated follow up for low-risk endometrial cancer

  • Use of ex-vivo models for personalising therapies

Dr Alessandro Rufini

  • Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

  • Investigating and exploiting metabolic vulnerabilities in carcinogenesis

  • Using circulating cell-free DNA for early detection of cancer

 

 
 

 

Personalised treatment in B cell malignancies

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies

  • Antibody therapy of lymphoid malignancies

  • Development and assessment of novel agents for therapy of B-cell malignancies

Dr Harriet Walter

  • Delivery of Phase I portfolio across haematological malignancies and solid tumours

  • Therapeutic drug development

Dr Matt Ahearne

  • Developing new diagnostic and therapeutic approaches in T-cell lymphoma

  • Targeting the microenvironment in B-cell lymphoma

Personalised medicine

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy

  • Molecular approaches to aid early detection of cancer

  • Molecular mechanisms of resistance to targeted therapy 

Dr David Guttery

  • Analysis of circulating cancer biomarkers through liquid biopsy

  • Molecular approaches to aid early detection of cancer

  • Molecular mechanisms of resistance to targeted therapy

  • Utility of artificial intelligence for early detection and improving therapy stratification

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies

  • Antibody therapy of lymphoid malignancies

  • Development and assessment of novel agents for therapy of B-cell malignancies

Professor Don J. L. Jones

  • Translation of candidate biomarkers to clinical use.

  • Use of high resolution LC-MS in the discovery and verification of biomarkers.

  • Investigation of protein quantification using Ion mobility.

  • Translation of candidate biomarkers to clinical use.

  • Use of high resolution LC-MS in the discovery and verification of biomarkers.

  • Investigation of protein quantification using Ion mobility.

Professor Bruno Morgan

  • Imaging applications to monitor drug therapy

  • Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT

Professor Dean Fennell

  • Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Professor Anne Thomas

  • The design and delivery of early phase clinical studies including chemoprevention strategies

  • Improving information exchange in oncology consultations

 

Pre clinical models enabling drug and biomarker discovery

 Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies

  • Antibody therapy of lymphoid malignancies

  • Development and assessment of novel agents for therapy of B-cell malignancies

Professor Anne Thomas

  • The design and delivery of early phase clinical studies including chemoprevention strategies

  • Improving information exchange in oncology consultations

Professor Catrin Pritchard

  • Mechanisms of RAS/RAF oncogene induced tumour development

  • RAF/MAPK signalling in normal and cancer cells

  • Ex vivo patient relevant drug testing platforms

Dr Esther Moss

  • Analysis of circulating endometrial cancer biomarkers through liquid biopsy

  • Molecular profiling for improved stratification to immunotherapies

  • Robotic surgery for management of endometrial cancer

  • Patient-initiated follow up for low-risk endometrial cancer

  • Use of ex-vivo models for personalising therapies

Dr Alessandro Rufini

  • Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol

  • Investigating and exploiting metabolic vulnerabilities in carcinogenesis

  • Using circulating cell-free DNA for early detection of cancer

Dr Cristina Tufarelli

  • Determine which repetitive elements are active in precancerous and cancerous cells

  • Understanding what causes activation of repetitive elements

  • Establish activation of which repetitive elements plays functional roles in cancer

  • Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy

 
 

Back to top
arrow-downarrow-down-3arrow-down-2arrow-down-4arrow-leftarrow-left-3arrow-left-2arrow-leftarrow-left-4arrow-rightarrow-right-3arrow-right-2arrow-right-4arrow-uparrow-up-3arrow-up-2arrow-up-4book-2bookbuildingscalendar-2calendarcirclecrosscross-2facebookfat-l-1fat-l-2filtershead-2headinstagraminstagraminstagramlinkedinlinkedinmenuMENUMenu Arrowminusminusrotator-pausec pausepinrotator-playplayc playplussearchsnapchatsnapchatthin-l-1thin-l-2ticktweettwittertwittertwitterwechatweiboweiboyoutubeyoutube